BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 25814163)

  • 21. Activity of telavancin and comparator antimicrobial agents tested against Staphylococcus spp. isolated from hospitalised patients in Europe (2007-2008).
    Mendes RE; Sader HS; Jones RN
    Int J Antimicrob Agents; 2010 Oct; 36(4):374-9. PubMed ID: 20598860
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ceftaroline Activity Tested Against Bacterial Isolates Causing Community-acquired Respiratory Tract Infections and Skin and Skin Structure Infections in Pediatric Patients From United States Hospitals: 2012-2014.
    Pfaller MA; Mendes RE; Castanheira M; Flamm RK; Jones RN; Sader HS
    Pediatr Infect Dis J; 2017 May; 36(5):486-491. PubMed ID: 28403050
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ceftaroline activity against bacterial pathogens frequently isolated in U.S. medical centers: results from five years of the AWARE surveillance program.
    Sader HS; Flamm RK; Streit JM; Farrell DJ; Jones RN
    Antimicrob Agents Chemother; 2015 Apr; 59(4):2458-61. PubMed ID: 25645844
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antimicrobial activity of ceftaroline tested against bacterial isolates causing respiratory tract and skin and skin structure infections in US medical centers in 2013.
    Sader HS; Farrell DJ; Mendes RE; Flamm RK; Castanheira M; Jones RN
    Diagn Microbiol Infect Dis; 2015 May; 82(1):78-84. PubMed ID: 25708896
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antimicrobial activity of daptomycin and selected comparators tested against bloodstream Staphylococcus aureus isolates from hemodialysis patients.
    Sader HS; Fritsche TR; Jones RN
    Int J Infect Dis; 2009 Mar; 13(2):291-5. PubMed ID: 18938097
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro activity of ceftaroline against clinical Staphylococcus aureus isolates collected during a national survey conducted in Belgian hospitals.
    Argudín MA; Dodémont M; Taguemount M; Roisin S; de Mendonça R; Deplano A; Nonhoff C; Denis O
    J Antimicrob Chemother; 2017 Jan; 72(1):56-59. PubMed ID: 27634917
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vitro evaluation of ceftaroline alone and in combination with tobramycin against hospital-acquired meticillin-resistant Staphylococcus aureus (HA-MRSA) isolates.
    Vidaillac C; Leonard SN; Rybak MJ
    Int J Antimicrob Agents; 2010 Jun; 35(6):527-30. PubMed ID: 20346632
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacodynamic comparison of different antimicrobial regimens against Staphylococcus aureus bloodstream infections with elevated vancomycin minimum inhibitory concentration.
    da Costa TM; Cuba GT; Morgado PGM; Nicolau DP; Nouér SA; Dos Santos KRN; Kiffer CRV
    BMC Infect Dis; 2020 Jan; 20(1):74. PubMed ID: 31973753
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Activity of ceftaroline against extracellular (broth) and intracellular (THP-1 monocytes) forms of methicillin-resistant Staphylococcus aureus: comparison with vancomycin, linezolid and daptomycin.
    Mélard A; Garcia LG; Das D; Rozenberg R; Tulkens PM; Van Bambeke F; Lemaire S
    J Antimicrob Chemother; 2013 Mar; 68(3):648-58. PubMed ID: 23188792
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Spectrum and potency of ceftaroline tested against leading pathogens causing skin and soft-tissue infections in Europe (2010).
    Farrell DJ; Flamm RK; Sader HS; Jones RN
    Int J Antimicrob Agents; 2013 Apr; 41(4):337-42. PubMed ID: 23466338
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Activity of the new cephalosporin ceftaroline against bacteraemia isolates from patients with community-acquired pneumonia.
    Morrissey I; Ge Y; Janes R
    Int J Antimicrob Agents; 2009 Jun; 33(6):515-9. PubMed ID: 19203863
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vitro activity of ceftaroline and comparator antimicrobials against European and Middle East isolates from complicated skin and skin-structure infections collected in 2008-2009.
    Morrissey I; Leakey A; Northwood JB
    Int J Antimicrob Agents; 2012 Sep; 40(3):227-34. PubMed ID: 22796201
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Activity of ceftobiprole against methicillin-resistant Staphylococcus aureus strains with reduced susceptibility to daptomycin, linezolid or vancomycin, and strains with defined SCCmec types.
    Farrell DJ; Flamm RK; Sader HS; Jones RN
    Int J Antimicrob Agents; 2014 Apr; 43(4):323-7. PubMed ID: 24411474
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Update of the activity of telavancin against a global collection of Staphylococcus aureus causing bacteremia, including endocarditis (2011-2014).
    Mendes RE; Sader HS; Smart JI; Castanheira M; Flamm RK
    Eur J Clin Microbiol Infect Dis; 2017 Jun; 36(6):1013-1017. PubMed ID: 28111724
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ceftaroline efficacy against high-MIC clinical Staphylococcus aureus isolates in an in vitro hollow-fibre infection model.
    Singh R; Almutairi M; Alm RA; Lahiri SD; San Martin M; Chen A; Ambler JE
    J Antimicrob Chemother; 2017 Oct; 72(10):2796-2803. PubMed ID: 29091195
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Spectrum and potency of ceftaroline tested against leading pathogens causing community-acquired respiratory tract infections in Europe (2010).
    Farrell DJ; Flamm RK; Jones RN; Sader HS
    Diagn Microbiol Infect Dis; 2013 Jan; 75(1):86-8. PubMed ID: 23146404
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ceftolozane/tazobactam activity tested against Gram-negative bacterial isolates from hospitalised patients with pneumonia in US and European medical centres (2012).
    Farrell DJ; Sader HS; Flamm RK; Jones RN
    Int J Antimicrob Agents; 2014 Jun; 43(6):533-9. PubMed ID: 24856078
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vitro activity of ceftaroline against bacterial pathogens isolated from skin and soft tissue infections in Europe, Russia and Turkey in 2012: results from the Assessing Worldwide Antimicrobial Resistance Evaluation (AWARE) surveillance programme.
    Karlowsky JA; Biedenbach DJ; Bouchillon SK; Iaconis JP; Reiszner E; Sahm DF
    J Antimicrob Chemother; 2016 Jan; 71(1):162-9. PubMed ID: 26503667
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ceftaroline fosamil salvage therapy: an option for reduced-vancomycin-susceptible MRSA bacteraemia.
    Espedido BA; Jensen SO; van Hal SJ
    J Antimicrob Chemother; 2015 Mar; 70(3):797-801. PubMed ID: 25406295
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [In vitro activity of ceftaroline against Spanish isolates of Staphylococcus aureus: a multicenter study].
    Tenorio-Abreu A; Gil Tomás J; Bratos Pérez MÁ; de la Iglesia Salgado A; Borrás Máñez M; Ortiz de Lejarazu Leonardo R; Ávila Alonso A; Colomina Rodríguez J; Pérez Cáceres JA; Saavedra Martín JM; Márquez Sanabria A; Domínguez Castaño A; de la Iglesia Salgado M
    Enferm Infecc Microbiol Clin; 2015 Feb; 33(2):101-4. PubMed ID: 25091384
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.